This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Best practice recommendations for liquid biopsy assay validations

October 12th, 2023
Association for molecular pathology publishes best practice recommendations for liquid biopsy assay validations
Overall percentage of reported cancer type(s) in at least 5% of included total and clinical validation publications. Note that some studies included multiple types of cancer. Tumor types not shown: head and neck (4%), lymphoma (4%), bone and soft tissue (3%), endocrine (3%), central nervous system (2%), not specified (2%), unknown primary (0.4%), eye (0.2%), and peripheral nervous system (0.2%). Credit: The Journal of Molecular Diagnostics (2023). DOI: 10.1016/j.jmoldx.2023.09.004

The Association for Molecular Pathology (AMP) has published a set of 13 best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and their related scientific publications.

The manuscript, "Recommendations for Cell-free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists (CAP)," was released online ahead of publication in The Journal of Molecular Diagnostics.

"One of the most important technological advances in molecular diagnostics over the past decade has been the ability to accurately detect and measure low abundance ctDNA in blood and body fluids," said Christina Lockwood, Ph.D., Chair of the AMP Liquid Biopsy Working Group and Professor and Division Head of Laboratory Genetics at the University of Washington School of Medicine.

"As with any emerging technology or methodology, the way these liquid biopsy assays are developed, validated, and reported can vary. This new report provides a set of evidence-based recommendations that can help promote standardization, transparency, and quality improvement among laboratories."

The AMP Clinical Practice Committee's Liquid Biopsy Working Group, including organizational representation from the American Society of Clinical Oncology (ASCO) and CAP, developed a set of recommendations for validating, reporting, and publishing clinical ctDNA assays.

The recommendations are based on a review of more than 1,200 publications that describe ctDNA assay performance in patients with lymphoma and solid tumor malignancies and subject matter expert professional experience. The recommendations include reporting key pre-analytical considerations and assay performance metrics.

"This new report was meant to summarize the current collective state of knowledge and assist clinical laboratory professionals with liquid biopsy assay validation," said Susan Hsiao, MD, Ph.D., 2023 AMP Clinical Practice Committee Chair and Associate Professor of Pathology and Cell Biology at Columbia University Irving Medical Center.

"As part of our ongoing commitment to improving clinical practice and patient care, AMP will continue to reassess and modify our recommendations as these technologies become more sensitive and additional trials are available to evaluate assay performance and clinical utility."

More information:
Christina M. Lockwood et al, Recommendations for Cell-Free DNA Assay Validations, The Journal of Molecular Diagnostics (2023). DOI: 10.1016/j.jmoldx.2023.09.004

Provided by Association for Molecular Pathology

Citation: Best practice recommendations for liquid biopsy assay validations (2023, October 12) retrieved 28 November 2024 from https://sciencex.com/wire-news/458584099/best-practice-recommendations-for-liquid-biopsy-assay-validation.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list